Romain Guièze

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

Romain Guièze, Vivian M. Liu, Daniel Rosebrock et al. · Cancer Cell · 2019 · 360 citations · Full text

Life Sciences, Cell Biology, Oncology +16

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study

Anne Quinquenel, Luc‐Matthieu Fornecker, Rémi Letestu et al. · Blood · 2019 · 129 citations · Full text

Life Sciences, Genetics, Hematology +10

Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study

Jacques Delaunay, Christian Récher, Arnaud Pigneux et al. · Blood · 2011 · 121 citations

Medicine, Oncology, Pharmacotherapy +15

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

Christophe Willekens, Odile Blanchet, Aline Renneville et al. · Haematologica · 2015 · 111 citations · Full text

Medicine, Hematology, Oncology +17

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL

Romain Guièze, Pauline Robbe, Ruth Clifford et al. · Blood · 2015 · 99 citations · Full text

Medicine, Genetics, Molecular Genetics +12